Heightened response of eosinophilic asthmatic patients to the CRTH 2 antagonist OC 000459
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: The CRTH 2 antagonist OC 000459 has previously been demonstrated to reduce airway inflammation and improve lung function in moderate persistent asthma. A study was conducted to determine the effect of lower once daily doses of OC 000459 and to define the phenotype of subjects most responsive to treatment. Methods: Adult subjects (percentage of predicted forced expiratory volume in 1 s (FEV1) 60–85%) were randomized to OC 000459 at three dose levels (25 mg once daily, 200 mg once daily or 100 mg twice daily) or placebo for 12 weeks (n = 117–125 per group, full analysis set). The primary endpoint was the change from baseline in prebronchodilator FEV1, and secondary endpoints included Asthma Control Questionnaire (ACQ) and Standardised Asthma Quality of Life Questionnaire [AQLQ(S)], and incidence of exacerbations and respiratory tract infections. Results: OC 459 caused a significant improvement in FEV1 compared with placebo at a dose of 25 mg once daily (P = 0.028). A similar increase was observed in the other dose groups, and the mean change in FEV1 in the pooled dose groups at endpoint was 95 ml greater than placebo (P = 0.024). In a post hoc analysis of atopic eosinophilic subjects with uncontrolled asthma, a mean increase in FEV1 of 220 ml was observed compared with placebo (P = 0.005). The mean increase in FEV1 was more marked in younger subjects in this group: for subjects aged ≤40 years, there was a mean increase of 355 ml compared with placebo (P = 0.007). Improvements in ACQ and AQLQ(S) were observed in both the full analysis set and the atopic eosinophilic subgroup. There was a lower incidence of exacerbations and respiratory infections in subjects treated with OC 000459. There were no drug‐related serious adverse events. Conclusions: OC 000459 is a safe and effective oral anti‐inflammatory agent, which achieved clinically meaningful improvements in lung function and asthma control in allergic asthmatics with an eosinophil‐dominant form of the disease. A dose of 25 mg given once daily was as effective as the higher doses studied.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cluster analysis and clinical asthma phenotypes
Haldar, P., Pavord, I. D., Shaw, D. E., Berry, M. A., Thomas, M., Brightling, C. E., Wardlaw, A. J., & Green, R. H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1754oc · Cited by 1,987 · cited 1×
“It is now recognized that asthma is a heterogeneous disease and considerable progress has been made in identifying distinct phenotypes that may respond differently to treatment (8, 9).”
Background
Cited by
New developments in mast cell biology
Kalesnikoff, J., & Galli, S. J. (2008) · Nature Immunology · doi:10.1038/ni.f.216 · Cited by 748
Targeting cell signaling in allergic asthma
Athari, S. S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0079-0 · Cited by 312
Muraro, A., Lemanske, R. F., Hellings, P. W., Akdis, C. A., Bieber, T., Casale, T. B., Jutel, M., Ong, P. Y., Poulsen, L. K., Schmid-Grendelmeier, P., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.03.010 · Cited by 284
The Complex Type 2 Endotype in Allergy and Asthma: From Laboratory to Bedside
Agache, I., Sugita, K., Morita, H., Akdis, M., & Akdis, C. A. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0529-x · Cited by 86
Marone, G., Galdiero, M. R., Pecoraro, A., Pucino, V., Criscuolo, G., Triassi, M., & Varricchi, G. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1555237 · Cited by 62
Metadata
- Authors
- Pettipher, R., Hunter, M. G., Perkins, C. M., Collins, L. P., Lewis, T., Baillet, M., Steiner, J., Bell, J., & Payton, M. A.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2014-07-14
- Volume
- 69
- Issue
- 9
- Pages
- 1223-1232
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2140688081
- Cited by
- 132
- References
- 1
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heightened response of eosinophilic asthmatic patients to the CRTH 2 antagonist OC 000459. https://app.cochat.ai/papers/10.1111/all.12451
- The paper
- Pettipher, R., Hunter, M. G., Perkins, C. M., Collins, L. P., Lewis, T., Baillet, M., Steiner, J., Bell, J., & Payton, M. A. (2014). Heightened response of eosinophilic asthmatic patients to the CRTH 2 antagonist OC 000459. Allergy. https://doi.org/10.1111/all.12451
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.